G6PC3

Across TCGA pan-cancer cohorts, G6PC3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated G6PC3 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher G6PC3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated G6PC3 expression acts as an unfavorable survival marker.

BLCA and SKCM are the cancer types where G6PC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.132	0.722	<.001	27	view →
SKCM	OS	Median	All	0.216	0.787	<.001	21	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

G6PC3–BLCA (OS)

Open the BLCA breakdown →